Fincar

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Fincar

Property Description
Active ingredient Finasteride
Form Oral, Film-coated Tablet
Pharmacological class 5-Alpha-Reductase Inhibitor
Common purpose Mitigate conditions driven by excess DHT
Origin Synthetic, 4-Azasteroid compound

Fincar: Defining the 5-Alpha-Reductase Inhibitor

Fincar is a synthetic, prescription-only medication whose active ingredient is the chemical compound finasteride. It is structurally defined as a 4-azasteroid compound and is categorized within the powerful pharmacological class of 5-alpha-reductase inhibitors.

The medication is a single-ingredient product, typically supplied as an oral, film-coated tablet intended for oral administration. This classification is clinically recognized for its targeted action; Finasteride selectively and preferentially inhibits the Type II 5α-reductase enzyme, differentiating its action from other inhibitors that block both Type I and Type II isoenzymes.

Composition, Form, and General Anti-Androgen Purpose

Fincar functions to produce its anti-androgen effect by intervening directly in the body’s hormonal metabolism. The active ingredient, finasteride, works by specifically blocking the intracellular enzyme Type II 5α-reductase, thereby interfering with the conversion of the hormone testosterone into the more potent androgen, dihydrotestosterone (DHT).

This selective inhibition causes a significant reduction in DHT concentrations in the blood serum and in hormone-sensitive tissues. The general purpose of this action is to mitigate the adverse physiological consequences associated with excessive DHT activity in adult males. The drug’s ability to achieve sustained control over this potent hormone forms the foundational basis for its overall therapeutic applications.

Regulatory References

  1. Source: NCBI StatPearls

What side effects are possible with Fincar?

Official Safety Profile and Adverse Reactions

The safety profile of Fincar (finasteride) is defined by officially documented adverse reactions and specific regulatory warnings from government health authorities, primarily focusing on sexual function, psychiatric health, and oncologic risks.

System-Organ Class Common Adverse Reactions (from trials) Serious Adverse Reactions (from reports)
Reproductive System Decreased libido, Erectile dysfunction, Ejaculation disorder, Gynecomastia. Testicular pain, Male infertility/Poor semen quality, Persistent sexual dysfunction.
Psychiatric Disorders Depression, Depressed mood, Suicidal ideation (Incidence Not Known).
Oncologic Increased risk of high-grade prostate cancer (class effect), Male breast cancer (post-marketing).

Special Safety Considerations

  • Contraindication for Pregnancy: Fincar is contraindicated in women who are or may become pregnant due to the potential risk of causing abnormalities of the external genitalia in a male fetus. Pregnant women must not handle crushed or broken tablets.
  • Duration of Exposure: Sexual adverse reactions may occur more frequently during the first year of treatment and have been reported to persist after discontinuation of the medication in some individuals.
  • PSA Monitoring Restriction: Finasteride causes a mandatory decrease in serum PSA levels. Any confirmed increase in PSA must be carefully evaluated for prostate cancer, even if the value is within the normal range for men not taking a 5α-reductase inhibitor.
  • Hypersensitivity: Immediate reactions, including rash, pruritus, urticaria, and Angioedema (swelling of the lips, face, and tongue), have been documented.

Overdose and Emergency Response

Overdose and when to seek help

Documented Overdose Profile

Regulatory documents state that clinical studies involving Fincar did not report any adverse effects following exposure to single oral doses up to 400 mg. Similarly, no adverse effects were documented when patients received high multiple daily doses up to 80 mg over a three-month period. This absence of specific acute toxicity manifestations at high exposures is a key component of the drug's regulatory overdose profile.

Official Emergency Action and Management

In the event of a suspected overdose, immediate medical attention should be sought. Government health authorities require contacting emergency services immediately if the affected individual displays general life-threatening symptoms, such as collapse, a seizure, difficulty breathing, or the inability to be awakened.

No specific antidote is known or officially recommended for Fincar overdose. Due to the lack of a targeted reversal agent, the regulatory guidance for management requires the use of symptomatic and supportive treatment. No specific population-related monitoring or management protocols are explicitly documented in the official overdose sections.

Connection to the Overall Overdose Profile

The official overdose profile for Fincar is defined by the absence of specific acute adverse events in clinical trials, coupled with the explicit regulatory statement that no specific treatment or antidote is available. Consequently, regulatory guidance mandates that management relies on symptomatic and supportive care, with the immediate trigger for emergency help being the presence of general severe systemic compromise or life-threatening symptoms.

Therapeutic Uses of Fincar

Fincar (finasteride) is commonly used to help with two primary conditions in men: benign prostatic hyperplasia (BPH) and male pattern hair loss (androgenetic alopecia). This medication is applied across domains where additional symptomatic support is needed.

For BPH, finasteride assists in addressing symptoms related to physical discomfort, such as frequent or difficult urination, often used during phases when symptoms become more noticeable. In scenarios involving recurrent or episodic manifestations like BPH, the medication contributes to easing the overall symptom load. For patients managing hair thinning, it is relevant for easing the symptoms that interfere with daily functioning.

The therapeutic approach supports patients during episodes of heightened discomfort across both indications. In situations where patients experience these fluctuating conditions, management may assist with maintaining functional stability.

“The relevant therapeutic contexts include supportive symptom management for benign prostatic hyperplasia and management for androgenetic alopecia.”

Quick Fact: Support for symptoms related to physical discomfort

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Official Eligibility and Contraindications

Fincar (Finasteride) is regulated by health authorities for use only in adult men. Its official eligibility profile is strictly defined by gender, age, reproductive status, and hypersensitivity. The medicine is not indicated for use in women.

Eligibility scope Regulatory Status
Populations for whom use is allowed: Adult Men
Populations for whom use is contraindicated: Pregnancy; Hypersensitivity to finasteride or any component
Age-related eligibility rules: Pediatric patients (under 18 years) are not indicated for use as safety and effectiveness have not been established
Condition-specific eligibility rules: Caution should be used in patients with liver function abnormalities
Pregnancy and lactation eligibility: Contraindicated in women who are or may become pregnant; this prohibition extends to handling crushed or broken tablets

The regulatory documents establish that Fincar is strictly contraindicated during pregnancy due to the risk of external genital abnormalities in a developing male fetus. Use in older adults requires no specific dosage adjustment, while patients with chronic renal insufficiency also require no adjustment based on official labeling. The most severe restrictions are placed on women of childbearing potential and any individual with a known allergy to the formulation.

What should I know about interactions with other medicines?

Fincar Interactions with other medicines and products

Official regulatory documents consistently report that no drug interactions of clinical importance have been identified with finasteride, the active ingredient in Fincar.

Documented Interaction Patterns

Finasteride is primarily metabolized by the cytochrome P450 3A4 (CYP3A4) enzyme system. However, the drug is officially documented as not significantly affecting the activity of the CYP-linked drug-metabolizing enzymes. This underpins the low-risk interaction profile.

Clinically meaningful interactions were not found when finasteride was tested with a broad range of commonly co-administered prescription medications, including:

  • Antipyrine
  • Digoxin
  • Propranolol
  • Theophylline
  • Warfarin
  • Acetaminophen
  • ACE Inhibitors and alpha-Blockers

Administration and Population Notes

Finasteride tablets may be administered with or without food. There are no official restrictions or mandatory timing separation rules for co-administered prescription medicines listed in the labeling.

While the elimination rate is documented as decreased in the elderly, this finding is officially stated to be without clinical significance. The effect of hepatic insufficiency (liver disease) on finasteride's clearance has not been formally studied.

Mechanism of Action

Targeted Enzyme Inhibition in Androgen Homeostasis

Fincar’s mechanism centers on its active component, finasteride, which functions as a highly selective competitive inhibitor of the enzyme 5-alpha-reductase (5alpha-R), predominantly the Type II and Type III isoenzymes. The drug binds to the enzyme, effectively blocking the crucial metabolic step of converting the precursor hormone testosterone into the more active androgen, dihydrotestosterone (DHT). This blockade produces a sustained suppression of DHT concentrations, initiating a cascading physiological consequence.

Modulation of Tissue-Specific Growth Signals

The core functional consequence of the mechanism is the modulation of Androgen Receptor (AR) signaling in DHT-dependent tissues. The substantial drop in local DHT levels prevents the hormone from binding to and activating the AR, thereby reducing the proliferation and growth signaling driven by DHT. This diminution of androgenic signaling alters the cellular lifecycle, leading to increased apoptosis (programmed cell death) and a proportional decrease in cell growth.

Alteration of Central Neurosteroid Pathways

Finasteride’s established effects extend to the central nervous system (CNS) by modulating the production of neuroactive steroids. Inhibition of 5alpha-R also leads to a reduction in the synthesis of neurosteroids (e.g., allopregnanolone) which function as modulators of GABA A receptors in the brain, representing a secondary, non-peripheral mechanistic effect on central nervous system pathways.

Dosage and Administration Information

How to Use Fincar: Official Administration Guidelines

Fincar (finasteride) usage is governed by strict, standardized protocols defining how the medicine must be administered. The drug is supplied as an oral, film-coated tablet, establishing the sole approved route of administration.


Official Dosing and Frequency

Administration is mandated as a once-daily regimen for both approved indications, promoting a simple, consistent schedule. Dosing is distinguished by the tablet strength used:

Indication Labeled Daily Dose
Benign Prostatic Hyperplasia (BPH) 5 mg once daily (monotherapy or combined use)
Androgenetic Alopecia (Hair Loss) 1 mg once daily

Procedural and Time Constraints

Fincar may be taken with or without food, granting flexibility in daily timing. Crucially, the film-coated tablet must be swallowed whole and must not be crushed or broken, ensuring proper drug delivery. If a dose is missed, instructions specify to skip the missed dose and resume the next dose at the regular time; users must not take a double dose.

Usage is characterized as a long-term commitment. For BPH, at least six months of continuous daily use is required to assess initial results. For androgenetic alopecia, three months or more of continuous use is necessary before a benefit can be observed and sustained.


Population-Specific Rules

Official labeling confirms that no dosage adjustment is required for use in older adults or in patients with renal impairment.

Recent Clinical Evidence

Research evidence / Overview of Studies for Fincar


Evidence for Use in Symptomatic Benign Prostatic Hyperplasia (BPH)

Fincar (finasteride) was studied for its application in men experiencing outcomes related to physical discomfort and functional issues arising from symptomatic BPH. The foundation of this evidence relies on large-scale Randomized Controlled Trials (RCTs), some of which were observed in study populations for several years. Researchers examined changes in patient-reported urological symptom scores and objective functional measures. Major studies explored whether finasteride was associated with differences in the reported frequency of outcomes related to BPH clinical events. The trials reported how symptoms evolved in the observed populations, and the pattern of change in prostate size was observed over several years. The long-term comparison of measured outcomes against some alpha-blocker medications findings did not describe clear distinctions in measured outcomes in finasteride monotherapy.

Evidence for Use in Male Pattern Hair Loss (Androgenetic Alopecia)

For the management of male pattern hair loss, Fincar was evaluated in multiple placebo-controlled RCTs typically lasting one to two years. These studies research examined men with mild to moderate thinning, focusing on the vertex and mid-scalp areas. Researchers monitored the change in hair count and used standardized photographic assessments to measure changes in overall hair appearance. The trials show patterns related to measured changes in hair count compared to the placebo groups, and the progression of visible changes appeared different in the groups receiving finasteride over several years of observation.

Areas of Uncertainty and Research Gaps

A key gap for both indications is that long-term outcomes are not fully established in the context of controlled trials after the drug is stopped; the natural course of symptoms following cessation was observed in some studies to revert toward the pre-treatment condition. Evidence quality varies across studies when non-standardized endpoints were evaluated in smaller observational settings, emphasizing that research provides context but not individual predictions.

Key Studies & References

  1. Finasteride in the Treatment of Men with Benign Prostatic Hyperplasia. Finasteride Study Group

Frequently Asked Questions (FAQ)

Common questions about Fincar (FAQ)


Q: Is Fincar the same kind of medicine as Proscar or Propecia?

A: Fincar and the brand-name drugs Proscar and Propecia share the same active ingredient, finasteride. Official regulatory documents confirm that generic medicines like Fincar are pharmaceutically equivalent to their brand-name counterparts. The primary difference often relates to the tablet strength and the condition each strength is indicated for.

Q: Can Fincar stop working after using it for a long time?

A: Official studies indicate that the beneficial effects of Fincar are typically maintained with continuous, long-term use. However, the medicine is not considered curative. If treatment is stopped, the effects will gradually reverse, and in some research, the original condition has been observed to return within about one year.

Q: Does Fincar affect blood donation eligibility?

A: Yes, taking Fincar can affect eligibility to donate blood or blood products. This is a precaution taken by blood donation centers because of the risk the active ingredient poses to a male fetus if the blood were given to a pregnant woman. Donation guidelines vary, and the final eligibility determination rests with the specific donation organization.

Q: Does Fincar interact with alcohol?

A: According to official regulatory documents, there is no specific clinically important interaction reported between Fincar and alcohol consumption. However, both the medication and alcohol are processed by the liver. A healthcare professional can address specific concerns about co-administration with alcohol.

Q: What should I do if I think Fincar is not agreeing with me?

A: If you feel that Fincar is not agreeing with you, official guidelines recommend monitoring for any severe or concerning changes. Severe reactions, such as swelling of the face or tongue (signs of an allergic reaction), may require immediate medical attention. A healthcare professional should be informed of any persistent or severe adverse reactions, including new or worsening psychiatric or sexual symptoms.

Q: Is it normal to experience headaches or dizziness when first starting Fincar?

A: Official product information notes that dizziness is a documented undesirable effect, and headaches are also sometimes reported, although these are typically not very common. Persistent or severe symptoms should be reported to a healthcare professional.

Q: How long does Fincar stay in my system after I stop taking it?

A: The half-life of finasteride, the active ingredient, is documented in official pharmacokinetics data as being approximately 4.7 to 8 hours. Based on this, the medication is expected to be largely cleared from the body's systemic circulation within a few days after the last dose is taken.

Q: Can Fincar be used by someone with diabetes or high blood pressure?

A: Official drug labeling does not list conditions such as diabetes or high blood pressure as specific reasons not to use Fincar. Furthermore, testing has not identified clinically significant interactions between finasteride and common cardiovascular medicines, including ACE inhibitors and alpha-blockers.

Q: What do official sources mean by 'contraindicated'?

A: In official medical terms, a contraindication is a specific condition or factor that makes a treatment potentially harmful, meaning the medication should not be used. Fincar is strictly contraindicated for use in women who are or may become pregnant because of the risk of causing harm to a developing male fetus.

Q: Is Fincar considered a curative or palliative medicine?

A: Fincar functions as a long-term management therapy for symptoms and progression, rather than a cure. Studies indicate that the therapeutic effects achieved are not permanent. The benefits begin to reverse when the medication is discontinued, with symptoms typically returning toward pre-treatment levels over time.

Q: How quickly does the body absorb Fincar after taking a tablet?

A: Official pharmacokinetics data shows that the active ingredient in Fincar is absorbed rapidly after the tablet is swallowed. The highest concentration of the drug in the blood, known as maximum plasma concentration, is generally reached about 1 to 2 hours after taking the dose.

Q: Is it safe to drive or operate machinery while using Fincar?

A: Official product information from regulatory sources states that Fincar has been assessed as having no or negligible influence on a person's ability to drive vehicles or operate machinery safely.

Q: What are the early signs that Fincar is starting to work for BPH?

A: While the medication begins to suppress the target hormone (DHT) within hours of the first dose, the physical changes take time to develop. Clinically noticeable improvements in urinary symptoms related to BPH are not typically observed until after 3 to 6 months of continuous daily use.

Q: Do studies suggest Fincar is less effective in certain ethnic groups?

A: Clinical studies involving the 5 mg dose of Fincar included diverse populations, such as Caucasian, African-American, Hispanic, and Asian men. Official study reports did not indicate any significant differences in the measured efficacy of the drug among these groups.

Q: Is Fincar known to cause stomach upset?

A: Official regulatory documents detailing the safety profile of Fincar do not list general gastrointestinal side effects, such as nausea or stomach upset, among the frequently reported adverse reactions observed in clinical trials.

Q: What are the alternative treatments mentioned in official documents for the conditions Fincar treats?

A: Official research evidence highlights that Fincar was studied both on its own (monotherapy) and in combination with other drug types, specifically alpha-blocker medications, in clinical trials for BPH. The regulatory documents focus primarily on the evidence for Fincar and its measured outcomes.

Q: Is it true that Fincar is only for older men?

A: The official eligibility criteria confirm Fincar is indicated for use in adult men, and its use is prohibited only in pediatric patients (under 18 years). While the BPH indication primarily affects older men, the androgenetic alopecia (hair loss) indication is for adult men across a wider age range.

Q: What is the main difference between the 1mg and 5mg tablets of Fincar?

A: The primary distinction between the 1 mg and 5 mg tablets is the dose and the specific condition it is indicated to treat. Official documents state that the 1 mg dose is for male pattern hair loss, and the 5 mg dose is for symptomatic benign prostatic hyperplasia (BPH).

Q: Is it necessary to have regular blood tests while on Fincar?

A: Monitoring of Prostate-Specific Antigen (PSA) levels is a required part of treatment with Fincar. Because the medicine lowers baseline PSA levels, official guidelines state that a healthcare provider must adjust the interpretation of these results to maintain effective screening for prostate cancer.

Q: What is the risk of rare, but serious side effects like liver problems?

A: Official safety data does not list general liver problems as a common or serious adverse reaction observed in clinical trials. However, the official product labeling notes that the effect of existing hepatic insufficiency (liver disease) on how the body processes the medication has not been formally studied.

Q: Can Fincar affect my mood or sleep patterns?

A: Adverse reactions related to mood are documented in official safety information, including reports of depression, depressed mood, and suicidal ideation. Conversely, changes to general sleep patterns are not explicitly listed among the adverse reactions in the official regulatory documents.

Q: Why is it important for a doctor to check for prostate cancer before starting Fincar?

A: Regulatory warnings emphasize that screening for prostate cancer should take place before starting treatment. This is crucial because Fincar lowers the levels of Prostate-Specific Antigen (PSA), which is a biomarker used for screening. Lowered PSA levels could potentially mask the detection of high-grade prostate cancer if it is already present.

Q: Can Fincar interact with herbal teas or supplements like saw palmetto?

A: Official documents report that no drug interactions of clinical importance have been identified. However, the active ingredient is processed by the CYP3A4 enzyme system. If herbal teas or supplements are known to affect this enzyme, they could potentially influence how the body handles Fincar.

Q: Does Fincar need to be taken at the same exact time every day?

A: Fincar is mandated as a once-daily regimen, which is key for maintaining a consistent therapeutic level in the body. While it does not need to be taken at the exact same minute each day and can be taken with or without food, consistent daily administration is the requirement noted in official instructions.

Q: What should I discuss with my healthcare provider before starting Fincar?

A: Before initiating treatment, official guidance advises discussing several factors with your provider. These include any pre-existing liver conditions, a history of depression or thoughts of self-harm, and providing a full list of all current medications and supplements. The requirement for ongoing PSA monitoring is another factor that is typically reviewed.

Q: What are the common reasons for stopping Fincar treatment?

A: Official clinical trial data indicates that the most common reasons patients stop Fincar treatment are the emergence of adverse reactions. These most frequently involve issues affecting sexual function, such as decreased libido or erectile dysfunction, and less often, psychiatric issues like depression.

How should Fincar be stored and disposed of?

How to Store and Dispose of Fincar?

Fincar (finasteride) must be stored at controlled room temperature, typically 20 C to 25 C (68 F to 77 F), in a dry place [1, 3]. It must be kept in the original, tightly closed container and protected from excessive heat and moisture [1, 3]. The medication must always be stored out of the reach of children [3].

Handling and Disposal

A critical handling precaution requires that women who are pregnant or may become pregnant must not handle crushed or broken tablets due to the risk of exposure to the active ingredient [1, 4]. For disposal, unused or expired Fincar should be taken to a drug take-back program [3]. If a take-back option is unavailable, the tablets should be mixed with an undesirable substance (such as dirt) and placed in a sealed container before being thrown in the household trash, avoiding disposal via sinks or toilets [3, 6].

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Fincar found in:

A-Z Index: